Theratechnologies Inc (TSE:TH)’s stock price crossed below its 50-day moving average during trading on Friday . The stock has a 50-day moving average of $5.38 and traded as low as $5.47. Theratechnologies shares last traded at $5.66, with a volume of 35,735 shares.
A number of equities analysts have weighed in on the stock. Mackie reduced their price objective on shares of Theratechnologies from C$8.15 to C$7.00 and set a “hold” rating for the company in a research report on Friday, July 12th. National Bank Financial reduced their price objective on shares of Theratechnologies from C$11.25 to C$8.25 and set a “sector perform” rating for the company in a research report on Friday, July 12th. Finally, Royal Bank of Canada reduced their price objective on shares of Theratechnologies from C$10.00 to C$8.00 in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. The company currently has an average rating of “Buy” and an average target price of C$9.56.
The stock’s 50-day moving average price is C$5.38 and its 200 day moving average price is C$6.61. The firm has a market capitalization of $426.32 million and a price-to-earnings ratio of -90.32. The company has a quick ratio of 2.09, a current ratio of 2.69 and a debt-to-equity ratio of 159.35.
A hedge fund recently bought a new stake in Theratechnologies stock. Monarch Partners Asset Management LLC acquired a new position in shares of Theratechnologies Inc (TSE:TH) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 447,990 shares of the company’s stock, valued at approximately $4,256,000. Monarch Partners Asset Management LLC owned about 0.58% of Theratechnologies at the end of the most recent quarter.
About Theratechnologies (TSE:TH)
Theratechnologies Inc, a specialty pharmaceutical company, addresses unmet medical needs to promote healthy living and improve quality of life among HIV patients. It offers EGRIFTA, for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy in Canada and the United States; and Trogarz, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients in the United States.
Read More: Futures Contract
Receive News & Ratings for Theratechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies and related companies with MarketBeat.com's FREE daily email newsletter.